Written Authority Required Drugs

Non-small cell lung cancer

The PBS subsidises crizotinib and osimertinib for patients with Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with crizotinib and osimertinib under the National Health Act 1953, section 85 for a patient with Stage IIIB or Stage IV NSCLC.

Patients must be eligible for the PBS and meet the restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing crizotinib and osimertinib.

Applications

Initial treatment

Apply for authority approval to prescribe PBS subsidised crizotinib to treat Stage IIIB or Stage IV NSCLC in writing and either:

All applications must include a completed:

Apply for authority approval to prescribe PBS subsidised osimertinib to treat Stage IIIB or Stage IV NSCLC in writing and either:

All applications must include a completed:

Initial grandfather treatment

For patients who received non-PBS subsidised crizotinib before 1 January 2019 to treat ROS1 positive Stage IIIB or Stage IV NSCLC, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

For patients who received non-PBS subsidised osimertinib before 1 February 2019 to treat Stage IIIB or Stage IV NSCLC, apply for initial grandfather authority approval in writing and either:

All applications must include the completed:

Continuing treatment

To apply for continuing treatment of Stage IIIB or Stage IV NSCLC with PBS subsidised crizotinib and osimertinib, call the PBS Complex Drugs Programs enquiry line.

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

This information was printed Friday 24 May 2019 from https://www.humanservices.gov.au/organisations/health-professionals/services/medicare/written-authority-required-drugs/drug-program-or-condition/non-small-cell-lung-cancer It may not include all of the relevant information on this topic. Please consider any relevant site notices at https://www.humanservices.gov.au/individuals/site-notices when using this material.

Page last updated: 22 February 2019